ACM
AXSM icon

ADAR1 Capital Management’s Axsome Therapeutics AXSM Stock Holding History

ADAR1 Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-19,661
Closed -$1.66M – 216
2024
Q4 		$1.66M Buy
19,661
+19,061
+3,177% +$1.75M 0.33% 57
2024
Q3 		$53.9K Buy
600
+300
+100% +$26.2K 0.01% 213
2024
Q2 		$24.1K Buy
+300
New +$22.2K ﹤0.01% 213

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

ADAR1 Capital Management's AXSM Position: Q1 2025 in Review

ADAR1 Capital Management sold out of Axsome Therapeutics (AXSM) in Q1 2025, closing a stake of 19,661 shares — an estimated $1.66M sold.

ADAR1 Capital Management first reported a position in AXSM in Q2 2024 and held it in 3 quarters. The position peaked at $1.66M in Q4 2024. 353 funds tracked by Wall St. Rank hold AXSM as of Q1 2025.

  • ADAR1 Capital Management reported no remaining Axsome Therapeutics position as of Q1 2025 after selling out during the quarter.
  • ADAR1 Capital Management sold 19,661 Axsome Therapeutics shares in Q1 2025, an estimated $1.66M.
  • ADAR1 Capital Management first reported a position in Axsome Therapeutics in Q2 2024 and held it in 3 quarters.
  • ADAR1 Capital Management's Axsome Therapeutics position peaked at $1.66M in Q4 2024.
  • 353 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2025.

Based on ADAR1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.